Table 1.
Summary of clinical data
| C | PC | VM | BM | CM | |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Total number | 15 | 26 | 30 | 20 | 12 |
| Median age | 66 | 57.6 | 60 | 66.3 | 62.1 |
| Deceased | 5 | ||||
| Pre-/postmenopausal | 1/14 | 10/16 | 6/24 | 2/18 | 2/10 |
| Tumour characteristics | |||||
| ER/PR positive | 15 | 17 | 16 | 1 | |
| HER2/neu positive | 8 | 11 | 3 | 11 | |
| Triple negative | 2 | 2 | |||
| Grading | |||||
| Well differentiated (G1) | 2 | 4 | 0 | 0 | |
| Moderately differentiated (G2) | 18 | 11 | 16 | 6 | |
| Poorly differentiated (G3) | 6 | 15 | 4 | 6 | |
| % of Ki67 positive cells (median) | 25% | 40% | 15% | 30% | |
| Other | 1 | ||||
BM bone metastases, C control group of healthy donors, CM cerebral metastases, ER estrogen receptor, Her2/neu human epidermal growth factor 2, PC primary cancer, PR progesterone receptor, VM visceral metastases